FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

Ítems similars

• FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
  per: Summers, Jeff, et al.
  Publicat: (2010)
• FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma
  per: Nair, Abhilasha, et al.
  Publicat: (2020)
• FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
  per: Fashoyin‐Aje, Lola, et al.
  Publicat: (2018)
• FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
  per: Kasamon, Yvette L., et al.
  Publicat: (2017)
• FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
  per: Larkins, Erin, et al.
  Publicat: (2017)